HK Stock Market Move | DUALITYBIO-B(09606) opens over 4% higher, included in Hang Seng Composite Index Constituent Stocks, Breast Cancer New Drug Phase III Clinical Trial achieved primary endpoints.

DUALITYBIO-B (09606) opened more than 4% higher, rising 4.63% to 380 Hong Kong dollars as of the time of writing, with a trading volume of 7.506 million Hong Kong dollars. On the news front, DUALITYBIO-B announced that starting from September 8, 2025, the company's shares will be included in the Hang Seng Composite Index and added to the list of stocks eligible for trading under the Shanghai-Hong Kong Stock Connect scheme by Hang Seng Indexes Company Limited. The inclusion of the company's shares in the Hang Seng Composite Index and the Shanghai-Hong Kong Stock Connect eligible securities list signifies a high level of recognition of the company's performance and value by the capital market. Qualified mainland Chinese investors can now directly invest in the company's shares listed on the Hong Kong Stock Exchange through the Shanghai Stock Exchange. It is expected that this inclusion will further expand the company's investor base and increase the trading liquidity of its shares. Furthermore, it is worth noting that on September 5, Ying En Biotech announced that, according to the evaluation by the Independent Data Monitoring Committee (IDMC), the Phase III clinical trial of DB-1303/BNT323 in HER2-positive unresectable or metastatic breast cancer patients who had previously received trastuzumab and taxane therapy has met the primary endpoint of progression-free survival (PFS) assessed by blinded independent central review (BICR) compared to the control group. The company plans to communicate with the Drug Evaluation Center of the National Medical Products Administration regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323. DB-1303/BNT323 is a clinical-stage HER2 ADCD candidate drug, currently being evaluated in two ongoing registration clinical trials and another potential global registration study. The company's partner, BioNTech SE, is preparing for the submission of a BLA for DB-1303/BNT323 in 2025.